Author/Editor | Kotseva, K; Wood, D; De Backer, G; De Bacquer, D; Turk, J; Keber, I; Marn, K; Salapura, V; Škof, E; Špan, M | |
Title | Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries | |
Type | članek | |
Source | Lancet | |
Vol. and No. | Letnik 357 | |
Publication year | 2001 | |
Volume | str. 995-1001 | |
Language | eng | |
Abstract | Background. Patients with coronary heart disease (CHD) are the top priority for preventive cardiology. The first EUROASPIRE survey among patients with established CHD in ine countries in 1995-96 showed substantial potential for risk reduction. A second survey (EUROASPIRE II) was done in 1999-2000 in the same countries to see whether preventive cardiology had improved since the first. We compared the proportion of patients in both studies who achieved the lifestyle, risk-factor, and theapeutic goals recommended by the Joint European Societies report on coronary prevention. Methods. The surveys were undertaken in the same selected geograohical areas and hospitals in the Czech Republic, Finland, France, Germany, Hungary, Italy, the Netherlands, Slovenia, and Spain. Consecutive patients (men and women <= 70 years of age) were identified after coronary-artry bypass graft or percutaneous transluminal coronary angioplasty, or a hospital admission with acute myocardial infarction of ischemia, and were interviewed at least 6 months later. Findings. 3569 and 3379 patients were interviewed in the first and second surveys, respectively. The prevelance of smoking remained almost unchanged at 19.4% vs 20.8%. The prevalence of obesity (body-mass index >= 30 kg/m2) increased substantially from 25.3% to 32.8%. The proportion with high blood pressure (>= 140/90 mm Hg) was virtually the same (55.4% vs 53.0%), whereas the prevalence of high total cholesterol concentrations (>= 5.0 mmol/L) decreased substantially from 86.2% to 58.8%. Aspirin or their antiplatelet therapy was as widely used in the second survey as the first (83.9% overall), and reported use of beta-blockers, angiotensin-converting-enzyme inhibitors, and especially lipid-lowering drugs increased. (Abstract truncated at 2000 characters). | |
Descriptors | CORONARY DISEASE LIFE STYLE RISK FACTORS EUROPE MULTICENTER STUDIES ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY MYOCARDIAL INFARCTION CORONARY ARTERY BYPASS PATIENT ADMISSION OBESITY HYPERTENSION HEALTH SURVEYS DIABETES MELLITUS CHOLESTEROL PLATELET AGGREGATION INHIBITORS ADRENERGIC BETA-ANTAGONISTS ANGIOTENSIN-CONVERTING ENZYME INHIBITORS ANTILIPEMIC AGENTS AGED |